Investment Rating - The investment rating for the company is "Buy" with a target of outperforming the industry index by more than 15% over the next six months [5][19]. Core Views - The company's profitability has significantly increased year-on-year, with a notable rise in net profit driven by the life nutrition products segment [2][11]. - The vitamin industry is expected to continue its upward trend, benefiting from increased market demand and price fluctuations [4][11]. - The company is implementing cost reduction and efficiency improvement measures across its two main segments to enhance competitiveness and support future growth [10][11]. Financial Performance Summary - For the first half of 2025, the company reported a revenue of 4.323 billion, a decrease of 1.87% year-on-year, while net profit increased by 113.52% to 673 million [1][2]. - The overall gross margin for the first half of 2025 was 39.82%, an increase of 4.43 percentage points compared to the same period in 2024 [2]. - The life nutrition products segment generated a revenue of 2.034 billion, a slight increase of 0.58% year-on-year, with a gross margin of 54.95%, up 15.41 percentage points [4][10]. Cash Flow and Financial Ratios - The net cash flow from operating activities for the first half of 2025 was 798 million, a significant increase of 281.20% year-on-year [3]. - The company’s cash and cash equivalents at the end of the period stood at 2.709 billion, an increase of 84.43% year-on-year [3]. - The projected earnings per share (EPS) for 2025 is 1.16, with corresponding P/E ratios of 13.5, 9.9, and 9.2 for the years 2025, 2026, and 2027 respectively [11].